（文章来源：每日经济新闻） 海通国际此前表示，近期多起BD密集落地，有望催化创新药行情。如10月16日普瑞金宣布与Kite达成 1.2亿美元首付款、总计最高可达15.2亿美元里程碑付款交易；维立志博宣布与Dianthus达成2000万美元 首付款、总金额最高可达10亿美元交易；10月17日翰森制药、奥赛康也分别宣布与罗氏、Visara达成交 易。 恒生医药ETF（159892）重仓股信达生物在港交所公告，其与武田制药达成全球战略合作，旨在加速推 进信达生物新一代IO及ADC疗法开发。本次合作包括两款后期在研疗法IBI363及IBI343，以及一款早期 研发项目IBI3001的选择权。 信达生物将获得12亿美元的首付款，包括以认购事项方式获得的1亿美元的战略股权投资。信达生物另 外有权获得合计最高可达102亿美元的潜在里程碑付款，本次合作交易总金额最高可达114亿美元。此 外，信达生物还将获得每个候选药物在大中华区以外的潜在销售分成。在美国市场，双方就IBI363将采 用利润损失共担模式。 ...

Core Insights - The Chinese biopharmaceutical industry is experiencing significant growth, with multiple large international deals being signed in a short period, indicating a shift from quantity to quality in innovation [1][6] - The integration of advanced technologies such as artificial intelligence and virtual cells is transforming drug development processes, allowing for more efficient and targeted research [2][3] - Chinese innovative drugs are gaining international recognition, with an increasing number of clinical trials presented at global academic conferences, showcasing their competitive efficacy against established global drugs [4][5] Group 1: International Collaborations - Shenzhen Pruijun Biopharmaceutical Co., Ltd. signed a collaboration with Gilead Sciences' Kite Pharma for in vivo editing therapy, with a potential total deal value of $1.64 billion [1] - Hansoh Pharmaceutical Group reached a licensing agreement with Roche for a targeted antibody-drug conjugate, with a potential total deal value of $1.53 billion [1] - The total value of China's innovative drug licensing agreements in the first half of 2025 is estimated to be nearly $66 billion, surpassing the total for the entire year of 2024 [6] Group 2: Technological Advancements - The Chinese biopharmaceutical industry is leveraging artificial intelligence and other cutting-edge technologies to enhance drug development, aiming to reduce traditional research timelines by 90% [2] - The establishment of digital twins and drug models for cancer patients is facilitating innovative research and accelerating new drug development [2][3] - The integration of AI, quantitative simulation, and high-throughput screening is improving research efficiency and enabling breakthroughs in drug delivery systems [3] Group 3: Clinical Recognition - The Chinese innovative drug, Moxilib Capsule, was presented at the 2025 European Society for Medical Oncology annual meeting, highlighting its clinical data [4] - Chinese drugs are increasingly participating in head-to-head trials against global leaders, demonstrating superior efficacy in various cancer treatments [4] - The focus on source innovation and disease mechanism-based research is leading to significant international achievements in the biopharmaceutical sector [5]

Investment Rating - The report maintains a positive outlook on the innovative drug and medical device industry, highlighting key targets for investment [5][24]. Core Insights - The innovative drug sector is experiencing high growth, with a focus on companies such as Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, and others. The report emphasizes the potential for value re-evaluation in these firms [5][24]. - Recent business development (BD) deals in the innovative drug sector are expected to catalyze market activity, with notable transactions including Jiangsu Heng Rui Medicine's agreement with Kite for a $1.20 billion upfront payment, potentially reaching $15.20 billion in total [5][24]. - The A-share pharmaceutical sector underperformed the broader market in the third week of October 2025, with the Shanghai Composite Index falling by 1.5% and the SW Biopharma index declining by 2.5% [7][18]. Summary by Sections 1. Continuous Focus on Innovative Drugs and Medical Devices - The report emphasizes the high growth potential in innovative drugs, with key investment targets including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, and others. Related targets include CSPC Innovation Pharmaceutical [5][24]. 2. A-Share Pharmaceutical Sector Performance - In the third week of October 2025, the A-share pharmaceutical sector saw a decline of 2.5%, underperforming the Shanghai Composite Index, which fell by 1.5%. The report notes that the sector's premium relative to all A-shares is currently at a normal level, with a relative premium rate of 74.5% [7][14][21]. 3. Hong Kong and U.S. Pharmaceutical Sector Performance - The report indicates that the Hong Kong and U.S. pharmaceutical sectors also underperformed, with the Hang Seng Healthcare index dropping by 5.8% and the S&P 500 Healthcare index increasing by only 0.7% during the same period [18][24].

来源：新浪基金 10月21日，港股通创新药板块震荡回暖，100%创新药研发标的——港股通创新药ETF（520880）午后 稳定涨势，场内收涨1.21%终结两连跌。成份股荣昌生物、云顶新耀涨超4%，权重股石药集团、翰森制 药跌1%有所拖累。 【创新药"新势力"——港股通创新药ETF（520880）：纯正创新药，聚焦真龙头，港股高弹性】 港股通创新药ETF（520880）被动跟踪恒生港股通创新药精选指数，该指数完全不含CXO，100%布局 创新药研发类公司，超7成仓位押注大市值创新药龙头，是精准表征创新药硬核力量的纯正创新药指 数。场外投资者可关注其联接基金：025221。 | | | 港股通创新药ETF (520880)标的指数 前十成份股权重高达71.63%,龙头优势显著 | | | --- | --- | --- | --- | | 代码 | 简称 | 权重(%) | 总市值(亿港元) | | 6160.HK | 三济神州 | 10.47 | 3.304 | | 1177.HK | 中国生物制药 | 10.01 | 1,527 | | 1093.HK | 石药集团 | 9.58 | 1,080 | | 18 ...

Market Overview - A-shares continued to rise strongly, with over 4,600 stocks closing in the green, and the Shanghai Composite Index increasing by 1.36% to surpass 3,900 points [1] - The ChiNext Index led the gains with a rise of 3.02%, while the Double Innovation Leading ETF surged by 4.28% [1] - Market sentiment showed significant improvement, with total trading volume reaching 1.89 trillion yuan [1] Sector Performance - The optical module sector experienced a strong rally, with Zhongji Xuchuang rising over 9%, nearing historical highs [3] - The AI-themed ETF, Huabao (159363), saw a substantial increase of 5.59%, recovering both the 10-day and 20-day moving averages, with a trading volume of 1.12 billion yuan [1][5] - The fruit chain concept also performed well, with the electronic ETF (515260) climbing by 4% during the session [1] Key Stocks - Zhongji Xuchuang recorded a five-day increase of over 27%, while other stocks in the optical module sector, such as Xinyisheng and Lian Te Technology, also saw significant gains [3][4] - The electronic ETF (515260) rose by 3.73%, recovering the 5-day moving average, driven by strong demand from the Apple supply chain [8][10] Investment Trends - Analysts suggest that the market style may be shifting, with a potential weakening of the dividend asset focus as technology stocks leverage a "window period" for recovery [3] - The demand for optical modules is expected to grow significantly, with projections indicating a rise in shipments from 800 million to over 2 billion units by 2026 [7] - The performance of the electronic sector is bolstered by the strong sales of the iPhone 17 series, which outperformed the iPhone 16 by 14% in the first ten days of sales [10][12] ETF Insights - The largest and most liquid AI-themed ETF (159363) has a recent scale exceeding 3.4 billion yuan, with an average daily trading volume of over 800 million yuan [7] - The electronic ETF (515260) has a significant weight in the Apple supply chain, with 43.43% of its components linked to Apple [10][12] - The Hong Kong Innovation Drug ETF (520880) showed signs of recovery, with a 1.21% increase, indicating strong buying interest [15]

10月21日，港股通创新药板块震荡回暖，100%创新药研发标的——港股通创新药ETF（520880）午后 稳定涨势，场内收涨1.21%终结两连跌。成份股荣昌生物、云顶新耀涨超4%，权重股石药集团、翰森制 药跌1%有所拖累。 值得关注的是，520880早尾盘震荡区间均涌现溢价，收盘溢价率更是超过1%，显示买盘尤为强劲。资 金面上，昨日3945万元逢跌净申购，近10日维度，累计超1.58亿元进场。 9月中旬以来，港股通创新药震荡走低，而创新药产业的态度和动作，成为波动行情中的"定心丸"。一 方面，美国第一药企辉瑞公司首席执行官直言，中国的生物医药生态系统"令人瞩目"，美国应少关注如 何拖慢中国，而更多思考如何适应新的竞争。另一方面，上周行业出现久违的BD"小高潮"，一天内三 个中国药企BD落地。 当下创新药怎么投？港股通创新药ETF（520880）基金经理丰晨成认为，创新药行情已经从"鸡犬升 天"的普涨行情，逐步过渡到关注"质量因子"的第二阶段。只有真正能落地、临床数据优异并具有商业 化能力的创新药龙头，才能取得财务的成功，并实现对于海外业务的"戴维斯双击"。 【创新药"新势力"——港股通创新药ETF（52088 ...

Market Performance Review - The recent market performance shows a pulse-like adjustment post-holiday, with the A-share market closing at 3883 points before the holiday and breaking through 3900 points before starting to adjust. On October 17, the market experienced its largest single-day decline since late August, with the Shanghai Composite Index and CSI 300 dropping 1.95% and 2.26% respectively [4][7][25] - In the short term, there is a clear shift in style, with growth stocks leading in August with an overall increase of over 10%, while small-cap growth and national index growth fell by 6.28% and 5.96% respectively in October, indicating a reversal in the previously lagging value style [4][10][20] A-share Market Outlook - The A-share market is expected to enter the second phase of a bull market, with a focus on technology as the main line. The current market resembles the 1999 bull market, driven by policy and cyclical patterns. The technology sector is expected to lead earnings recovery, which will drive structural market performance [4][35] - The valuation of growth stocks is under scrutiny, with liquidity being a core driver of the bull market. Current valuations for technology stocks have not yet reached a 15% overvaluation threshold, suggesting continued focus on AI applications in the coming year [4][35] Hong Kong Market Outlook - The Hong Kong market is anticipated to benefit from enhanced pricing power of Chinese companies and stable liquidity, with a focus on pharmaceuticals and e-commerce as new catalysts. The Hang Seng Index and Hang Seng Technology Index saw significant fluctuations, with the latter experiencing a decline of over 10% in October after a 13.9% increase in September [4][25][28] - The pharmaceutical sector has shown resilience, with innovative drug companies performing well despite overall market adjustments. The upcoming Double 11 shopping festival is expected to provide a boost to the e-commerce sector [4][25][28]

Core Viewpoint - The A-share and Hong Kong stock markets have experienced significant gains, with the Hong Kong Stock Connect Innovative Drug ETF (159570) seeing a nearly 2% increase and a trading volume approaching 2 billion yuan, indicating strong investor interest and liquidity in the innovative drug sector [1][3]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (159570) has a current scale exceeding 21 billion yuan, leading its peers in both scale and liquidity [1]. - As of October 20, the ETF has seen a net inflow of over 1.7 billion yuan in the past 20 days [1]. - Major stocks within the ETF, such as Innovent Biologics, CanSino Biologics, and 3SBio, have shown positive performance, with increases exceeding 2% [3]. Group 2: Business Development (BD) Trends - The innovative drug sector continues to thrive, with five business development (BD) deals totaling $4.266 billion reported over two days [3]. - Notable transactions include Hansoh Pharmaceutical with a total deal amount of $1.53 billion and Prigen with $1.64 billion [3]. - The total number of license-out transactions in China from January 1 to October 17, 2025, reached 135, with upfront payments totaling $4.976 billion and total deal amounts reaching $102.996 billion, reflecting strong international interest in Chinese innovative drug assets [5]. Group 3: Upcoming Catalysts - The fourth quarter is expected to see an acceleration in BD activities, with a focus on data from the ESMO conference [5]. - Chinese scholars are leading 23 LBA studies at the 2025 ESMO, showcasing various innovative drugs and highlighting China's growing influence in the global pharmaceutical landscape [7]. - The anticipated release of clinical data from the ESMO conference may lead to a revaluation of Chinese innovative drug pipelines and their corresponding stocks [7]. Group 4: Global Pricing Dynamics - Recent agreements between Pfizer and AstraZeneca with the U.S. government on Most Favored Nation (MFN) pricing have exceeded expectations, potentially impacting global sales forecasts for innovative drugs [8][9]. - Pfizer's agreements cover aspects such as pricing for existing and new drugs, direct sales, and tariff exemptions, which could enhance the market potential for innovative drugs [9][10]. - If MFN pricing trends continue, the peak global sales forecast for innovative drugs, including those licensed out from China, may significantly increase [10].

Market Performance - The Hang Seng Index rose by 2.4% to 25,859 points, while the Hang Seng China Enterprises Index increased by 2.5% to 9,233 points[1] - Total turnover in Hong Kong stocks was HKD 239.2 billion, lower than HKD 314.6 billion on the previous Friday, indicating market caution despite the rise[1] - Key sectors such as Energy, Consumer Discretionary, Information Technology, and Conglomerates saw increases of 2.8%, 3.3%, 3.2%, and 2.0% respectively, while Materials fell by 0.7%[1] Economic Indicators - China's Q3 GDP grew by 4.8%, surpassing the market expectation of 4.7%[3] - Industrial output in September rose by 6.5%, exceeding the forecast of 5.0%[3] - Retail sales increased by 3.0% year-on-year, aligning with expectations[3] Real Estate Trends - New home sales in 30 major cities reached 1.98 million square meters, down 25.4% year-on-year but improved from a previous decline of 41.4%[3] - New housing starts fell by 15.0% to 55.98 million square meters, a smaller decline compared to 19.8% in August[3] - The price index for new residential properties in 70 major cities dropped by 2.7% year-on-year, with first, second, and third-tier cities experiencing declines of 0.7%, 2.1%, and 3.4% respectively[3] Sector Highlights - Li Auto (9863 HK) saw a 6.2% increase in stock price after its founder and shareholders increased their holdings[4] - UBTECH (9880 HK) surged by 9.8% following a procurement order worth HKD 126 million for its latest humanoid robot[4] - The Hang Seng Healthcare Index rose by 1.3%, with major pharmaceutical companies showing stable performance despite market concerns[4]

Group 1 - The core viewpoint indicates that the innovative drug sector in Hong Kong is showing clear signs of bottoming out, supported by several factors [1] - BD (Business Development) transactions have started to recover since October, with historical data showing that transactions from October to January account for over 50% of the annual total, and transaction amounts can reach 60% to 70% of the yearly total [1] - Positive data from ESMO (European Society for Medical Oncology) has emerged, with several important clinical studies, such as AK112 and 3SB707, showing promising results, which is expected to catalyze further trading and stock price increases [1] - The valuation of innovative drugs has reached an absolute bottom, with some companies having little room for further decline [1] Group 2 - As of October 21, 2025, the National Securities Hong Kong Stock Connect Innovative Drug Index (987018) shows mixed performance among its constituent stocks, with notable gainers including CloudTop New Drug (01952) up 5.29% and Zai Lab (09688) up 1.80%, while major decliners include Juno Therapeutics-B (02617) down 6.82% [2] - The Hong Kong Innovative Drug ETF (159286) closely tracks the National Securities Hong Kong Stock Connect Innovative Drug Index and has seen a slight increase of 0.22%, with the latest price at 0.93 yuan [2] - As of September 30, 2025, the top ten weighted stocks in the National Securities Hong Kong Stock Connect Innovative Drug Index account for 71.83% of the index, including companies like BeiGene (06160) and Innovent Biologics (09926) [2]